Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's  What You Should Know
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know

Shares of Immunovant, Inc. (IMVT) have gained 0.4% over the past four weeks to close the last trading session at $26, but there could still be a solid upside left in the stock if short-term price

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus

Immunovant, Inc. (IMVT) reported third-quarter fiscal 2026 net loss of 61 cents per share, narrower than the Zacks Consensus Estimate of a loss of 72 cents. The company had reported a loss of 76